Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEW YORK - AIM ImmunoTech Inc. (NYSE American: AIM), a small-cap pharmaceutical company with a market capitalization of $69 million, resumed trading on the NYSE American exchange Tuesday under its original ticker symbol "AIM" and a new CUSIP number 00901B303. The stock, currently trading at $0.33, has ranged between $0.19 and $0.62 over the past 52 weeks.
The immuno-pharma company, which focuses on developing therapeutics for cancers, immune disorders and viral diseases including COVID-19, announced the trading resumption in a press release statement. According to InvestingPro analysis, the company maintains a FAIR financial health score, with a solid current ratio of 1.68 indicating stable short-term liquidity.
AIM’s lead product is Ampligen (rintatolimod), described as a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist immuno-modulator. The company reports the drug is currently in clinical trials for various cancers, viral diseases and immune system disorders.
The company, based in Ocala, Florida, did not provide details regarding any previous trading suspension or the circumstances that led to the resumption of trading. For deeper insights into AIM’s valuation and growth prospects, InvestingPro subscribers have access to over 30 additional financial metrics and exclusive analysis.
AIM ImmunoTech develops pharmaceutical products aimed at treating multiple types of cancers and immune-related conditions. The company maintains research and development operations focused on its Ampligen product candidate.
The trading resumption marks a continuation of the company’s public market presence on the NYSE American exchange, which specializes in listing small-cap companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.